We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Arch Biopartners Engages Cantox to Devise Drug Development Plan for GH501a

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Arch Biopartners Engages Cantox to Devise Drug Development Plan for GH501a"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Arch Biopartners Inc has announced that it has engaged Intertek Cantox to devise the drug development plan for the Company's lead compound, GH501a.

The Company recently identified GH501a as a potential treatment for non-small cell lung cancer and pancreatic cancer.

The drug development plan is expected to be complete by the end of 2011 and will focus in detail on the steps that need to be completed by the Company in order to submit an Investigational New Drug ("IND") application and pursue subsequent human trials.